Viewing nowBillguard 50 mg (Vildagliptin)
Vildagliptin 50mg
Tablet · Prescription medication
Samjin Pharmaceutical Co., Ltd.

MFDS item code 202200365 · Approved 2022.01.20 · Insurance code 647805350
Improvement of glycemic control in type 2 diabetes mellitus
This drug is used as an adjunctive treatment to help patients with type 2 diabetes achieve better blood sugar control along with meal management and exercise therapy. It can be used alone or in combination with other medications as needed to enhance therapeutic effects. This helps improve blood sugar levels and assists in the management of diabetes.
For monotherapy, or when administered with metformin in patients who have not previously received pharmacological treatment for diabetes, this drug is administered at 50mg once daily in the morning or at 100mg per day, divided into 50mg twice daily in the morning and evening. When glycemic control is inadequate with metformin or thiazolidinedione monotherapy, the recommended dose of this drug when administered with metformin or a thiazolidinedione is 100mg per day, divided into 50mg twice daily in the morning and evening. When glycemic control is inadequate with sulfonylurea monotherapy, the recommended dose of this drug when administered with a sulfonylurea is 50mg once daily in the morning. In this patient group, vildagliptin 100mg once daily was not more effective than 50mg once daily. When glycemic control is inadequate with combination therapy of a sulfonylurea and metformin, the recommended dose of this drug as add-on therapy (triple therapy) is 100mg per day, divided into 50mg twice daily in the morning and evening. When glycemic control is inadequate with insulin therapy (insulin alone or in combination with metformin), the recommended dose of this drug as add-on therapy is 100mg per day, divided into 50mg twice daily in the morning and evening. This drug may be taken with or without food. Doses exceeding 100mg per day are not recommended. When this drug is used in combination with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia. If you forget to take this drug, take it as soon as you remember and take the next dose at the usual time. If you remember close to the time of your next dose, skip the missed dose. Do not take a double dose at one time to make up for a missed dose. This drug is not recommended for patients with hepatic impairment whose ALT or AST levels exceed 2.5 times the upper limit of normal before treatment. Patients with mild renal impairment (creatinine clearance ≥50mL/min): No dose adjustment is required. Patients with moderate or severe renal impairment, or end-stage renal impairment (ESRD): A dose of 50mg once daily is recommended. (See section 3, General Precautions, subsection 2, in Precautions for Use.)
This drug should not be used in patients who are allergic to the active substance or other ingredients. It should also not be administered to patients with type 1 diabetes or diabetic ketoacidosis. Because this drug contains lactose, it should not be used in patients with lactose intolerance or genetic lactose-related issues. While using this drug, there may rarely be abnormal liver function, so regular liver function tests should be performed before and during administration. If liver function levels persist at three times the normal upper limit or symptoms such as jaundice appear, the use of this drug should be stopped. In some heart failure patients, the use of this drug is not recommended, so consult a physician if there is a history of heart disease. Skin lesions such as blisters or ulcers may appear, so the condition of the skin should be carefully monitored. There is a risk of acute pancreatitis, so if symptoms such as abdominal pain or vomiting occur, immediate medical attention should be sought. When used with medications that can cause hypoglycemia, such as sulfonylureas, caution for hypoglycemic symptoms should be exercised, and dosage adjustments may be necessary. If symptoms such as dizziness occur, it is advisable to avoid driving or operating machinery. It is not safe for pregnant or breastfeeding women to use this drug. There is no need for special dosage adjustments in the elderly; however, safety and efficacy have not been established in children and adolescents, so it is not recommended. In cases of overdose, supportive measures are necessary, and this drug is not removed by dialysis, so caution is advised. Keep out of reach of children and be careful not to transfer it to another container.
Not everyone experiences these, and they can vary from person to person.
This drug is sensitive to air and moisture, so keep the bottle tightly closed and sealed. It is also recommended to store in a cool place below 30 degrees Celsius.
White to light yellow circular tablet
30 tablets/box [10 tablets/PTP X 3]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowVildagliptin 50mg
Tablet · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Vildagliptin 50mg
Tablet · Prescription medication
Ahn-Guk New Pharm Co., Ltd.

Vildagliptin 50mg
Tablet · Prescription medication
AhnGuk Pharmaceuticals Co., Ltd.

Vildagliptin 50mg
Tablet · Prescription medication
Genewon Science Co., Ltd.

Vildagliptin 50mg
Tablet · Prescription medication
Lightpharmtech Co., Ltd.

Vildagliptin 50mg
Tablet · Prescription medication
White Life Sciences Co., Ltd.
Vildagliptin 50mg
Tablet · Prescription medication
Pharmgen Science Co., Ltd.

Vildagliptin 50mg
Tablet · Prescription medication
Mothers Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.